BIOMAT Database Logo BIOMAT Database Logo

Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. 1985

M T Aguado, and J D Lambris, and G C Tsokos, and R Burger, and D Bitter-Suermann, and J D Tamerius, and F J Dixon, and A N Theofilopoulos

C3-bearing immune complexes and C3 activation products were detected by using two monoclonal antibodies, one specific for a neoantigenic determinant on C3c and the other for C3d. To quantitate immune complexes, the anti-C3c or anti-C3d antibodies were fixed to microtiter plates and reacted with test plasma. The binding of C3-bearing immune complexes in this plasma was then measured with radioisotope- or enzyme-labeled anti-human IgG. To test for C3 breakdown products, solid-phase monoclonal antibody to the C3d neoantigen was reacted with EDTA-plasma samples, and fixed iC3b or C3d was measured with a polyclonal anti-C3 antibody. Patients with autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's syndrome, and paracoccidioidomycosis were found to contain immune complexes bearing C3b/iC3b or C3d. In most conditions, there were more C3d-containing immune complexes than C3b/iC3b. Although CR1 (C3b receptors) rapidly converted immune complex-bound iC3b to C3dg/C3d and lupus patients had reduced CR1, no correlation between the state of C3 on circulating immune complexes or levels of immune complexes and CR1 numbers was seen. However, levels of C3-fixing ICs correlated with levels of C3 activation products. This assay system with monoclonal antibodies to neoantigens expressed on activated, but not native, C3 provides sensitive and specific means for detecting and classifying C3-fixing immune complexes and for assessing C3 activation.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D010229 Paracoccidioidomycosis A mycosis affecting the skin, mucous membranes, lymph nodes, and internal organs. It is caused most often by Paracoccidioides brasiliensis. It is also called paracoccidioidal granuloma. Blastomyces brasiliensis Infections,Blastomycosis, South American,Paracoccidioides Infection,Paracoccidioides Infections,Paracoccidioidomycoses,Blastomyces brasiliensis Infection,Paracoccidioidal Granuloma,Paracoccidioides brasiliensis Infection,Granuloma, Paracoccidioidal,Infection, Blastomyces brasiliensis,Infection, Paracoccidioides,Infection, Paracoccidioides brasiliensis,Infections, Paracoccidioides brasiliensis,Paracoccidioidal Granulomas,Paracoccidioides brasiliensis Infections,Paracoccidioidomycose,South American Blastomycosis
D011951 Receptors, Complement Molecules on the surface of some B-lymphocytes and macrophages, that recognize and combine with the C3b, C3d, C1q, and C4b components of complement. Complement Receptors,Complement Receptor,Complement Receptor Type 1,Receptor, Complement
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D000936 Antigen-Antibody Complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES. Immune Complex,Antigen-Antibody Complexes,Immune Complexes,Antigen Antibody Complex,Antigen Antibody Complexes,Complex, Antigen-Antibody,Complex, Immune,Complexes, Antigen-Antibody,Complexes, Immune
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

M T Aguado, and J D Lambris, and G C Tsokos, and R Burger, and D Bitter-Suermann, and J D Tamerius, and F J Dixon, and A N Theofilopoulos
Relationship between complement activation and renal deposition of immune complexes made with IgG2a monoclonal antibodies.
September 2001, Clinical immunology (Orlando, Fla.),
M T Aguado, and J D Lambris, and G C Tsokos, and R Burger, and D Bitter-Suermann, and J D Tamerius, and F J Dixon, and A N Theofilopoulos
Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes.
December 1988, Journal of immunology (Baltimore, Md. : 1950),
M T Aguado, and J D Lambris, and G C Tsokos, and R Burger, and D Bitter-Suermann, and J D Tamerius, and F J Dixon, and A N Theofilopoulos
Monoclonal antibodies against neoantigens of the terminal C5b-9 complex of human complement.
August 1985, Bioscience reports,
M T Aguado, and J D Lambris, and G C Tsokos, and R Burger, and D Bitter-Suermann, and J D Tamerius, and F J Dixon, and A N Theofilopoulos
Binding of soluble immune complexes to Raji lymphocytes. Role of receptors for complement components, C1q and C3-C3b.
April 1978, Immunology,
M T Aguado, and J D Lambris, and G C Tsokos, and R Burger, and D Bitter-Suermann, and J D Tamerius, and F J Dixon, and A N Theofilopoulos
Complement C3b receptors on erythrocytes, circulating immune complexes, and complement C3 split products in patients with primary Sjögren's syndrome.
July 1986, Arthritis and rheumatism,
M T Aguado, and J D Lambris, and G C Tsokos, and R Burger, and D Bitter-Suermann, and J D Tamerius, and F J Dixon, and A N Theofilopoulos
Detection of complement activation using monoclonal antibodies against C3d.
May 2013, The Journal of clinical investigation,
M T Aguado, and J D Lambris, and G C Tsokos, and R Burger, and D Bitter-Suermann, and J D Tamerius, and F J Dixon, and A N Theofilopoulos
Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies.
August 1982, Journal of immunology (Baltimore, Md. : 1950),
M T Aguado, and J D Lambris, and G C Tsokos, and R Burger, and D Bitter-Suermann, and J D Tamerius, and F J Dixon, and A N Theofilopoulos
Interaction between immune complexes and C3b receptors on erythrocytes.
May 1986, Clinical immunology and immunopathology,
M T Aguado, and J D Lambris, and G C Tsokos, and R Burger, and D Bitter-Suermann, and J D Tamerius, and F J Dixon, and A N Theofilopoulos
Complement-mediated solubilization of immune complexes and their interaction with complement C3 receptors.
January 1985, Complement (Basel, Switzerland),
M T Aguado, and J D Lambris, and G C Tsokos, and R Burger, and D Bitter-Suermann, and J D Tamerius, and F J Dixon, and A N Theofilopoulos
Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation.
January 1988, Arthritis and rheumatism,
Copied contents to your clipboard!